Cargando…
Polyelectrolyte‐Enrobed Cancer Cells in View of Personalized Immune‐Therapy
Targeting the immune system with a personalized vaccine containing cues derived from the patient's malignancy might be a promising approach in the fight against cancer. It includes neo‐antigens as well as nonmutated tumor antigens, preferentially leading to an immune response that is directed t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473321/ https://www.ncbi.nlm.nih.gov/pubmed/28638786 http://dx.doi.org/10.1002/advs.201700050 |
_version_ | 1783244275060834304 |
---|---|
author | Lybaert, Lien Ryu, Keun Ah De Rycke, Riet Chon, Alfred C. De Wever, Olivier Vermaelen, Karim Y. Esser‐Kahn, Aaron De Geest, Bruno G. |
author_facet | Lybaert, Lien Ryu, Keun Ah De Rycke, Riet Chon, Alfred C. De Wever, Olivier Vermaelen, Karim Y. Esser‐Kahn, Aaron De Geest, Bruno G. |
author_sort | Lybaert, Lien |
collection | PubMed |
description | Targeting the immune system with a personalized vaccine containing cues derived from the patient's malignancy might be a promising approach in the fight against cancer. It includes neo‐antigens as well as nonmutated tumor antigens, preferentially leading to an immune response that is directed to a broader range of epitopes compared to strategies involving a single antigen. Here, this paper reports on an elegant method to encapsulate whole cancer cells into polyelectrolyte particles. Porous and nonaggregated microparticles containing dead cancer cells are obtained by admixing mannitol and live cancer cells with oppositely charged polyelectrolytes, dextran sulfate (anionic polysaccharide), and poly‐l‐arginine (cationic polypeptide) prior to atomization into a hot air stream. It shows that the polyelectrolyte‐enrobed cancer cells, upon redispersion in phosphate buffered saline buffer, are stable and do not release cell proteins in the supernatant. In vitro experiments reveal that the particles are nontoxic and strongly increase uptake of cell lysate by dendritic cells. In vitro assessment of antigen presentation by dendritic cells reveal the potential of the polyelectrolyte‐enrobed cancer cells as promotors of antigen cross‐presentation. Finally, it is demonstrated that the immunogenicity can be enhanced by surface adsorption of a polymer‐substituted TLR7‐agonist. |
format | Online Article Text |
id | pubmed-5473321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-54733212017-06-21 Polyelectrolyte‐Enrobed Cancer Cells in View of Personalized Immune‐Therapy Lybaert, Lien Ryu, Keun Ah De Rycke, Riet Chon, Alfred C. De Wever, Olivier Vermaelen, Karim Y. Esser‐Kahn, Aaron De Geest, Bruno G. Adv Sci (Weinh) Full Papers Targeting the immune system with a personalized vaccine containing cues derived from the patient's malignancy might be a promising approach in the fight against cancer. It includes neo‐antigens as well as nonmutated tumor antigens, preferentially leading to an immune response that is directed to a broader range of epitopes compared to strategies involving a single antigen. Here, this paper reports on an elegant method to encapsulate whole cancer cells into polyelectrolyte particles. Porous and nonaggregated microparticles containing dead cancer cells are obtained by admixing mannitol and live cancer cells with oppositely charged polyelectrolytes, dextran sulfate (anionic polysaccharide), and poly‐l‐arginine (cationic polypeptide) prior to atomization into a hot air stream. It shows that the polyelectrolyte‐enrobed cancer cells, upon redispersion in phosphate buffered saline buffer, are stable and do not release cell proteins in the supernatant. In vitro experiments reveal that the particles are nontoxic and strongly increase uptake of cell lysate by dendritic cells. In vitro assessment of antigen presentation by dendritic cells reveal the potential of the polyelectrolyte‐enrobed cancer cells as promotors of antigen cross‐presentation. Finally, it is demonstrated that the immunogenicity can be enhanced by surface adsorption of a polymer‐substituted TLR7‐agonist. John Wiley and Sons Inc. 2017-05-02 /pmc/articles/PMC5473321/ /pubmed/28638786 http://dx.doi.org/10.1002/advs.201700050 Text en © 2017 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Full Papers Lybaert, Lien Ryu, Keun Ah De Rycke, Riet Chon, Alfred C. De Wever, Olivier Vermaelen, Karim Y. Esser‐Kahn, Aaron De Geest, Bruno G. Polyelectrolyte‐Enrobed Cancer Cells in View of Personalized Immune‐Therapy |
title | Polyelectrolyte‐Enrobed Cancer Cells in View of Personalized Immune‐Therapy |
title_full | Polyelectrolyte‐Enrobed Cancer Cells in View of Personalized Immune‐Therapy |
title_fullStr | Polyelectrolyte‐Enrobed Cancer Cells in View of Personalized Immune‐Therapy |
title_full_unstemmed | Polyelectrolyte‐Enrobed Cancer Cells in View of Personalized Immune‐Therapy |
title_short | Polyelectrolyte‐Enrobed Cancer Cells in View of Personalized Immune‐Therapy |
title_sort | polyelectrolyte‐enrobed cancer cells in view of personalized immune‐therapy |
topic | Full Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473321/ https://www.ncbi.nlm.nih.gov/pubmed/28638786 http://dx.doi.org/10.1002/advs.201700050 |
work_keys_str_mv | AT lybaertlien polyelectrolyteenrobedcancercellsinviewofpersonalizedimmunetherapy AT ryukeunah polyelectrolyteenrobedcancercellsinviewofpersonalizedimmunetherapy AT deryckeriet polyelectrolyteenrobedcancercellsinviewofpersonalizedimmunetherapy AT chonalfredc polyelectrolyteenrobedcancercellsinviewofpersonalizedimmunetherapy AT deweverolivier polyelectrolyteenrobedcancercellsinviewofpersonalizedimmunetherapy AT vermaelenkarimy polyelectrolyteenrobedcancercellsinviewofpersonalizedimmunetherapy AT esserkahnaaron polyelectrolyteenrobedcancercellsinviewofpersonalizedimmunetherapy AT degeestbrunog polyelectrolyteenrobedcancercellsinviewofpersonalizedimmunetherapy |